ES2545688T3 - Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide - Google Patents

Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide Download PDF

Info

Publication number
ES2545688T3
ES2545688T3 ES07818398.5T ES07818398T ES2545688T3 ES 2545688 T3 ES2545688 T3 ES 2545688T3 ES 07818398 T ES07818398 T ES 07818398T ES 2545688 T3 ES2545688 T3 ES 2545688T3
Authority
ES
Spain
Prior art keywords
score
methods
risk
disease progression
rheumatoid arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07818398.5T
Other languages
English (en)
Spanish (es)
Inventor
Johann Karl
Veit Peter Grunert
Wolfgang Rollinger
Norbert Wild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2545688T3 publication Critical patent/ES2545688T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES07818398.5T 2006-09-29 2007-09-25 Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide Active ES2545688T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06020645 2006-09-29
EP06020645 2006-09-29
EP06021887 2006-10-19
EP06021887 2006-10-19
PCT/EP2007/008313 WO2008037420A1 (en) 2006-09-29 2007-09-25 Assessing the risk of disease progression for a patient with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
ES2545688T3 true ES2545688T3 (es) 2015-09-15

Family

ID=38859738

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07818398.5T Active ES2545688T3 (es) 2006-09-29 2007-09-25 Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide

Country Status (6)

Country Link
US (1) US8058013B2 (enExample)
EP (1) EP2074428B1 (enExample)
JP (1) JP2010506147A (enExample)
CA (1) CA2663730A1 (enExample)
ES (1) ES2545688T3 (enExample)
WO (1) WO2008037420A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038104A1 (en) * 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
WO2011047358A1 (en) 2009-10-15 2011-04-21 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US20130246097A1 (en) * 2010-03-17 2013-09-19 Howard M. Kenney Medical Information Systems and Medical Data Processing Methods
JP5786020B2 (ja) 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
US8883427B2 (en) 2010-06-30 2014-11-11 New York University Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments
JP5924659B2 (ja) * 2010-10-14 2016-05-25 国立大学法人 長崎大学 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー
US20140142861A1 (en) * 2010-11-06 2014-05-22 Oklahoma Medical Research Foundation Biomarkers For Predicting Progressive Joint Damage
US11531033B2 (en) * 2013-03-15 2022-12-20 Exagen Inc. Methods for treating and diagnosing systemic lupus erythematosus
JP2015061592A (ja) * 2013-08-21 2015-04-02 コニカミノルタ株式会社 超音波診断装置、超音波画像処理方法およびコンピュータ読み取り可能な非一時的な記録媒体
CA2943821A1 (en) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
EP3155439A4 (en) 2014-06-10 2018-03-14 Crescendo Bioscience Biomarkers and methods for measuring and monitoring axial spondyloarthritis disease activity
CA3207751A1 (en) 2015-09-29 2017-04-06 Laboratory Corporation Of America Holdings Biomarkers and methods for assessing psoriatic arthritis disease activity
WO2017058999A2 (en) 2015-09-29 2017-04-06 Crescendo Bioscience Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal
GB201603571D0 (en) * 2016-03-01 2016-04-13 Univ Warwick Markers for skeletal disorders
WO2021087116A1 (en) * 2019-10-30 2021-05-06 Cd Diagnostics, Inc. Biomarkers of early osteoarthritis
CN114089632B (zh) * 2021-11-15 2023-08-18 陕西师范大学 基于模糊逻辑的风湿免疫疾病特征识别方法及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105893D0 (en) * 1991-03-20 1991-05-08 Orion Yhtymae Oy Bone resorption assay based on a peptide liberated during collagen degradation
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU3746295A (en) * 1994-10-17 1996-05-06 Osteometer Biotech As Estimation of the fragmentation pattern of collagen in body fluids and the diagnosis of disorders associated with the metabolism of collagen
FR2752842B1 (fr) 1996-08-30 1998-11-06 Biomerieux Sa Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide
NL1004539C2 (nl) 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
CA2309534A1 (en) 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
FR2773157B1 (fr) 1997-12-30 2001-10-05 Bio Merieux Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide
IL136889A0 (en) * 1998-01-09 2001-06-14 Pfizer Matrix metalloprotease inhibitors
EP1240180A2 (en) 1999-12-21 2002-09-18 Innogenetics N.V. Peptides designed for the diagnosis and treatment of rheumatoid arthritis
NL1019540C2 (nl) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
CA2552425C (en) * 2004-02-27 2018-02-06 F. Hoffmann-La Roche Ag Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
US20060063162A1 (en) * 2004-09-23 2006-03-23 Deng David X Biological marker for inflammation
WO2006098401A1 (ja) * 2005-03-16 2006-09-21 The University Of Tokushima 関節リウマチ罹患リスクの測定方法
US7713521B2 (en) * 2005-08-12 2010-05-11 Schering Corporation MCP1 fusions

Also Published As

Publication number Publication date
JP2010506147A (ja) 2010-02-25
EP2074428A1 (en) 2009-07-01
US20090270272A1 (en) 2009-10-29
WO2008037420A1 (en) 2008-04-03
US8058013B2 (en) 2011-11-15
EP2074428B1 (en) 2015-07-01
CA2663730A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
ES2545688T3 (es) Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide
Favero et al. Erosive hand osteoarthritis: latest findings and outlook
Khella et al. An evidence-based systematic review of human knee post-traumatic osteoarthritis (PTOA): timeline of clinical presentation and disease markers, comparison of knee joint PTOA models and early disease implications
Chen et al. Osteoarthritis: toward a comprehensive understanding of pathological mechanism
King et al. Joint fluid proteome after anterior cruciate ligament rupture reflects an acute posttraumatic inflammatory and chondrodegenerative state
Stürmer et al. Severity and extent of osteoarthritis and low grade systemic inflammation as assessed by high sensitivity C reactive protein
Punzi et al. Inflammatory osteoarthritis of the hand
Cuzdan Coskun et al. Adiponectin: is it a biomarker for assessing the disease severity in knee osteoarthritis patients?
Song et al. Possible involvement of serum and synovial fluid resistin in knee osteoarthritis: cartilage damage, clinical, and radiological links
Clementi et al. Efficacy of a single intra-articular injection of ultra-high molecular weight hyaluronic acid for hip osteoarthritis: a randomized controlled study
O'Leary et al. Characterization of facet joint cartilage properties in the human and interspecies comparisons
Wu et al. Dickkopf-1 in ankylosing spondylitis: review and meta-analysis
Qin et al. Expression of NF-κB and osteopontin of synovial fluid of patients with knee osteoarthritis
Ekbote et al. A descriptive analysis of 14 cases of progressive-psuedorheumatoid-arthropathy of childhood from south India: review of literature in comparison with juvenile idiopathic arthritis
Xu et al. Contributions of joint damage-related events to gout pathogenesis: new insights from laboratory research
Duan et al. Infrapatellar fat pads participate in the development of knee osteoarthritis in obese patients via the activation of the NF‑κB signaling pathway
Jørgensen et al. The regional turnover of cartilage collagen matrix in late-stage human knee osteoarthritis
Kamiab et al. Role of Interleukin-17 family cytokines in disease severity of patients with knee osteoarthritis
Chu et al. Cartilage oligomeric matrix protein and matrix metalloproteinase-3 expression in the serum and joint fluid of a reversible osteoarthritis rabbit model
Tian et al. TNFAIP8 family gene expressions in the mouse tail intervertebral disc injury model
Tollefson et al. Inflammatory synovial biomarkers and state of the tibiofemoral joint in the post-surgical settings: a narrative review
Haider et al. Plasma and synovial osteopontin levels, are they associated with disease severity of primary knee osteoarthritis in Egyptian patients?
Tachikart et al. Seno-suppressive molecules as new therapeutic perspectives in rheumatic diseases
Abdel-Magied et al. Diagnostic potential of ultrasound in systemic lupus erythematosus patients with joint involvement: relation to anticyclic citrullinated peptide (anti-CCP), disease activity and functional status
von Kroge et al. Do clinical parameters reflect local bone metabolism in heterotopic ossification after septic or aseptic THA?